Clinical Trials Browser

Phase 2 × Recruiting × Neoplasm, Residual × Clear all

NCT06500273 2026-05-20

ALPHA3

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07136077 2026-05-15

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

NCT06993675 2026-05-13

ROTATE

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual

NCT04434040 2026-05-04

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07069595 2026-04-22

PREDICT-RD

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04768426 2026-04-13

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2 Recruiting

CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT06951646 2026-03-09

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05708235 2026-03-05

MiRaDoR

Phase 2 Recruiting

Breast Neoplasms, Neoplasm, Residual

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Phase 2 Recruiting

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT06828991 2025-10-20

GOLD

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT06668558 2025-09-19

VERDI

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07021677 2025-06-15

DARA_T_ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06414148 2025-06-05

EpLCART

Phase 2 Recruiting

Lymphoma, Recurrence, Neoplasm, Residual

NCT06718244 2025-05-23

Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06886074 2025-03-20

Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05904106 2024-12-02

VINCENT

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT05965479 2024-11-12

DECIPHER

Phase 2 Recruiting

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms, Neoplasm, Residual

NCT06608732 2024-11-05

Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.

Phase 2 Recruiting

Burkitt Lymphoma, Neoplasm, Residual

NCT06498752 2024-08-06

MRD-Guided Consolidation Therapy Following Definitive Radiotherapy in Esophageal Cancer

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Neoplasm, Residual

NCT06536959 2024-08-05

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Phase 2 Recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06253650 2024-06-13

TRINITY

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms, Neoplasm, Residual

NCT06158269 2023-12-06

DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Neoplasm, Residual